枸橼酸西地那非可改善慢性血液透析患者的勃起功能障碍。
Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients.
作者信息
Ghafari A, Farshid B, Afshari A T, Sepehrvand N, Rikhtegar E, Ghasemi K, Hatami S
机构信息
Department of Internal Medicine, Urmia University of Medical Sciences, Imam Khomeini Training Hospital, Urmia, Iran.
出版信息
Indian J Nephrol. 2010 Jul;20(3):142-5. doi: 10.4103/0971-4065.70845.
Erectile dysfunction (ED) is common among patients with end-stage renal disease (ESRD), who undergo hemodialysis (HD). The aim of this study was to evaluate the safety and effectiveness of sildenafil in male HD patients with ED. Twenty-seven HD patients were recruited for this prospective, randomized, double-blind, placebo-controlled, clinical trial study of sildenafil during a period of 1 week. Efficacy was assessed by using the International Index of Erectile Function (IIEF) before and 1 week after treatment. Baseline demographic and clinical features were similar in both the groups. There was a weak correlation between ED and duration of undergoing dialysis (P = 0.073). There was significant relationship between sildenafil usage and improvement in erectile function (P < 0.0001). Placebo improved significantly the erectile function (P = 0.016), perhaps by psychological way. However, sildenafil had a more significant effect than placebo in increasing IIEF score among HD patients (P = 0.00 compared to 0.016). Sildenafil is effective and safe for treating ED among HD patients.
勃起功能障碍（ED）在接受血液透析（HD）的终末期肾病（ESRD）患者中很常见。本研究的目的是评估西地那非对患有ED的男性HD患者的安全性和有效性。27名HD患者被招募参加这项关于西地那非的前瞻性、随机、双盲、安慰剂对照临床试验研究，为期1周。通过在治疗前和治疗1周后使用国际勃起功能指数（IIEF）来评估疗效。两组的基线人口统计学和临床特征相似。ED与透析时间之间存在弱相关性（P = 0.073）。西地那非的使用与勃起功能改善之间存在显著关系（P < 0.0001）。安慰剂显著改善了勃起功能（P = 0.016），可能是通过心理方式。然而，在增加HD患者的IIEF评分方面，西地那非比安慰剂有更显著的效果（P = 0.00对比0.016）。西地那非对治疗HD患者的ED有效且安全。
Zotero 插件